Skip to main content
. Author manuscript; available in PMC: 2022 Oct 14.
Published in final edited form as: FASEB J. 2022 Oct;36(10):e22514. doi: 10.1096/fj.202200765R

Figure 4: Exogenous CNL reduces Ara-C and/or Venetoclax-induced drug resistant mechanisms:

Figure 4:

MOLM-14 (A, B) and MV4-11 (C) cells made resistant to Venetoclax or drug-naïve were treated with the indicated drug combinations (MOLM-14: CNL 15μM, Ara-C 1.25μM, venetoclax 50nM; MV4-11: CNL 15 μM, Ara-C 1.25 μM) for 24 hours, harvested and proteins extracted. Western blots were performed and quantitated via densitometry. Loading was normalized to actin (3A, 3B) or to tubulin (3C). Shown is mean +/− S.E.M. of relative protein expression to vehicle for proteins indicated, N=3–5. Of note, we chose tubulin instead of actin for the MV4-11 drug-resistant cell line as actin levels were significantly reduced in this cell lines compared with wild type (data not shown). Even though, CNL elevated tubulin in wild type but not the drug-resistant cell line. CNL reduced Mcl-1 and P-S317-Chk1 significantly in the drug-resistant cell line. A: *, p<0.05 vs. vehicle; #, p<0.05 vs. triple. B:*, p<0.005 vs. Ara-C; #, p<0.005 vs. triple. C: *, p<0.05 vs. vehicle drug-naïve; ; ^, p=0.05 vs. vehicle drug-naive; #, P<0.02 vs. Ara-C drug-naive; <, p=0.048 vs. Ara-C drug-naive. Representative blots are shown beneath each graph.